Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors

Journal of Women's Health

Volumn 22, Issue 2, 2013, Pages 132-140

  Spangler, Leslie ^a   Yu, Onchee ^a   Loggers, Elizabeth ^a,b   Boudreau, Denise M ^a,c  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE;

ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; OSTEOPOROSIS; POSTGRADUATE EDUCATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT REFUSAL; WOMEN'S HEALTH;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BONE AND BONES; BONE DENSITY; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84873615486     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2012.3687     Document Type: Article

References (37)

1. U.S. Preventive Services Task Force (USPSTF). Screening for osteoporosis: recommendation statement. Am Fam Physician 2011;83:1197-1200.
2. National Osteoporosis Foundation (NOF). Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: NOF, 2010. Available at www.nof.org/sites/default/files/pdfs/NOF-ClinicianGuide2009-v2007.pdf Accessed July 2012.
3. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force report: Bone health in cancer care. J Natl Compr Canc Netw 2009;7 (Suppl 3):S1-S32.
4. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 2008;34 (Suppl 1):S3-18.
5. De Angelis R, Tavilla A, Verdecchia A, et al. Breast cancer survivors in the United States: Geographic variability and time trends, 2005-2015. Cancer. 2009;115:1954-1966.
6. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-3796.
7. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of ar-omatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23:619-629. (Pubitemid 46224240)
8. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
9. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84. (Pubitemid 26022463)
10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388. (Pubitemid 28439961)
11. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bispho-sphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057. (Pubitemid 46606220)
12. Khan MN, Khan AA. Cancer treatment-related bone loss: A review and synthesis of the literature. Curr Oncol 2008;15: S30-40.
13. Neuner JM, Yen TW, Sparapani RA, Laud PW, Nattinger AB. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int 2011;22:2847-2855.
14. Ito K, Blinder VS, Elkin EB. Cost-effectiveness of fracture prevention in postmenopausal women who receive ar-omatase inhibitors for early breast cancer. J Clin Oncol 2012;30:1468-1475.
15. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
16. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling Jr. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-421. (Pubitemid 46548643)
17. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:3076-3080.
18. Lix LM, Yogendran MS, Leslie WD, et al. Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases. J Clin Epidemiol 2008;61:1250-1260.
19. Newton KM, LaCroix AZ, Heckbert SR, Abraham L, McCulloch D, Barlow W. Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. Diabetes Care 2003;26:2810-2816. (Pubitemid 37205551)
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383. (Pubitemid 17055592)
21. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Aya-nian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 2007;25:1074-1081. (Pubitemid 46596759)
22. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159: 702-706. (Pubitemid 38405384)
23. Gibson K, O'Bryant CL. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. J Oncol Pharm Pract 2008;14:139-145.
24. Tham YL, Sexton K, Weiss HL, Elledge RM, Friedman LC, Kramer RM. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. J Support Oncol 2006;4:295-298, 304.
25. Lewiecki EM. Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep 2005;3:75-83.
26. National Osteoporosis Foundation (NOF). Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation 2008. www.nof.org/professionals/Clinicians-Guide.htm
27. Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366-375.
28. Centers for Medicare & Medicaid Services (CMS). National coverage determination (NCD) for bone (mineral) density studies (150.3). Available at www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId= 256&ver=251 Accessed July 2012.
29. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334-338. (Pubitemid 34260741)
30. Solomon DH, Brookhart MA, Gandhi TK, et al. Adherence with osteoporosis practice guidelines: A multilevel analysis of patient, physician, and practice setting characteristics. Am J Med 2004;117:919-924. (Pubitemid 40075559)
31. Cohen K, Maier D. Osteoporosis: Evaluation of screening patterns in a primary-care group practice. J Clin Densitom 2008;11:498-502.
32. Ramsey SD, Cheadle AD, Neighbor WE, et al. Relative impact of patient and clinic factors on adherence to primary care preventive service guidelines: An exploratory study. Med Care 2001;39:979-989. (Pubitemid 33603655)
33. American Society of Health-System Pharmacists. AHFS drug information 2011. Bethesda, MD: Authority of the Board of the American Society of Health-System Pharmacists, American Hospital Formulary Service, 2011.
34. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004;10:5717-5723. (Pubitemid 39180947)
35. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007;43:2523-2531. (Pubitemid 350086940)
36. Tang SC. Women and bone health: Maximizing the benefits of aromatase inhibitor therapy. Oncology 2010;79:13-26.
37. Laliberte MC, Perreault S, Jouini G, Shea BJ, Lalonde L. Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: A systematic review and meta-analysis. Osteoporos Int 2011;22: 2743-2768.